DOT1L and acute myeloid leukemia: Pinometostat (EPZ-5676), a low-molecular-weight inhibitor of DOT1L, caused an antiproliferative effect at submicromolar concentrations [71,99,104] and is currently being examined in phase II clinical trials for AML (NCT03724084).